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COMMENTARY
A Unique Researcher Identifier
for the Physician Payments Sunshine Act
Daniel Carpenter, PhD
Steven Joffe, MD, MPH
THEPHYSICIANPAYMENTS SUNSHINEACT (PPSA) PROM-ises a new era of transparency for the US health caresystem. Signed into lawonMarch 23, 2010, the PPSAis part of the Patient Protection and Affordable Care
Act of 2009.1 The PPSA requires medical product compa-
nies to report to the Department of Health and Human Ser-
vices (DHHS) a range of “transfers of value” to covered re-
cipients (physicians and teaching hospitals). With some
exceptions, these transfers and their value will be publicly
disclosed.
The PPSA constitutes an important step toward compre-
hensive, user-friendly, point-of-need availability of in-
formation about physicians’ and investigators’ financial
relationships with industry. Ideally, any user of amajor bio-
medical research database such as PubMed, clinicaltrials
.gov, orNIHRePORTER should be able to access aWeb page
listing an author’s, investigator’s, or grantee’s financial
relationships by following an embedded hyperlink. How-
ever, limitations of the PPSAwill prevent realization of this
ambitious vision. Straightforward, inexpensivemeasures to
remedy these omissions would greatly enhance the value
of the PPSA.
Limits of the PPSA
Data disclosed in response to the PPSA will be useful for
many purposes, including greater consciousness of physi-
cian payments and increased ability to monitor physician
behavior. These data will also facilitate independent analy-
sis of the relationships between financial ties and research
and clinical outcomes, not only allowing the research com-
munity to monitor conflicts of interest but also encourag-
ing companies to scrutinize their financial relationshipswith
individual researchers.
The PPSA, however, has important limitations. First, it
does not cover payments to nonphysician investigators.
Second, it does not incorporate a unique identifier that
would permit linkages among databases. Although the
PPSA requires companies to include physicians’ National
Provider Identifiers (NPIs) in their annual submissions to
DHHS, it explicitly prohibits DHHS from disclosing NPIs
in its public reports—and in any case, NPIs would not
encompass nonphysician recipients. Together, these limi-
tations constrain the PPSA’s reach and inhibit the ability
of interested parties to use these data to understand the
nature and effects of industry’s financial relationships
with the biomedical research enterprise.
These omissions are important because of pervasive
concerns that industry financial relationships may contrib-
ute bias to research.2 Although the entity that funded a
study is usually clearly identified, it is much more difficult
to learn whether an investigator has received payments.
This gap in available data gives rise to 3 related limitations.
First, without unique investigator identifiers, universities
and research hospitals have difficulty learning of payments
to their faculty or staff. Second, investigators’ incentives to
be concerned about the fact or appearance of conflict of
interest are diminished when their research cannot easily
be linked to their financial relationships. Third, it is diffi-
cult to examine whether payments are linked to research
outcomes.3
Remedying the Deficiencies in the PPSA
The effectiveness of disclosure requires high-quality
information that is accessible through a user-friendly
interface. Four simple steps would allow the PPSA to ful-
fill its promise. First, an entity with access to payments
data submitted to DHHS and the capability to function in
a clearinghouse role could establish and administer a
database of unique researcher identifiers. Second, DHHS
could mandate that companies include recipients’
researcher identifiers in their annual reports. Third,
DHHS could include recipients’ researcher identifiers in
its annual public disclosure of companies’ payments.
Fourth, a means to incentivize registration of nonphysi-
cian and non-US investigators will be required. For
example, institutional review boards might condition study
approval on investigators’ provision of their researcher
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identifiers, or biomedical journals might require inclusion
of authors’ researcher identifiers with submitted manu-
scripts.
Although several organizations could in theory admin-
ister the proposed system and its linkages to other data-
bases, the National Library of Medicine (NLM) may be
best positioned to perform this task. First, the NLM
already houses many of the major databases that would
be linked through the researcher identifier system. Sec-
ond, as a component of DHHS, the NLM could fulfill the
clearinghouse role without the administrative complexity
required to move data between executive departments or
outside the federal government.
The idea of a researcher identifier is hardly new. Sev-
eral proposals,4-8 one of which seeks to establish “an
alphanumeric string that uniquely identifies an individual
scientist, much the way that a Digital Object Identifier
(DOI) uniquely identifies a paper, book or other schol-
arly publication,”8 are currently circulating. The goal of
existing proposals is to minimize attribution error (ie,
attributing an article to the wrong “D Smith”).5 The
potential of a unique identifier to foster transparency of
financial relationships in biomedical research has not,
however, been previously recognized.
The federal government has long required the registra-
tion and unique identification of physicians as well as of or-
ganizations such as hospitals and health plans. Thus, ample
legal authority exists for the creation of these identifiers
through rulemaking.
Benefits of a Unique Researcher Identifier
With a system of unique researcher identifiers in place,
readers of articles or abstracts using PubMed or other
online bibliographic databases would be able to hyperlink
to a publicly available page listing the investigator’s pay-
ments. Similarly, patients and others seeking studies on
clinicaltrials.gov would be able to access data on investi-
gators’ financial relationships. In addition, analysts would
be able to examine whether payments are concentrated
among certain kinds of researchers or in certain subfields
of research, as well as whether they are systematically
associated with particular research outcomes.
Many of the benefits of disclosure systems come from re-
cipients’ knowledge that their behavior is being observed.
Given the ease of access and aggregation associated with a
unique identifier, researcherswould be induced to thinkmore
carefully about the payments they accept. Companies may
police their payment patternsmore carefully. The claim that
payments are directed to the scholars with the greatest ex-
pertise can be rigorously tested.
Although any such system has limitations, these are likely
to be modest relative to the gains. Investigators would have
one-time compliance costs for a system thatwould serve other
purposes. Given the current administration’s transparency
initiative,9 the net cost of informatics andWebhostingwould
likely be modest.With the prior existence of both the PPSA
and a nascent researcher identification system, it is un-
likely that the present proposal would chill scientific dis-
covery. Moreover, although nonphysician and non-US in-
vestigators would not initially be covered (the PPSA does
not mandate disclosure of payments to these profession-
als), a researcher identifier would create a basis for extend-
ing disclosure, through voluntary efforts or future man-
dates, to these scientists. Recent efforts to compel Public
Health Service–funded researchers to disclose their finan-
cial relationships are a step in this direction,10 but are lim-
ited in that many investigators do not receive Public Health
Service funding.
Conclusion
The goal of PPSA—to enhance transparency of financial
relationships between the medical products industry and
those individuals who influence the practice of medicine
or the conduct of research—is a worthy one. The devel-
opment of a unique identifier system that permits linkage
of individuals’ payments data to their entries in major
biomedical research databases and facilitates extension of
disclosure practices to nonphysician investigators will
enhance the likelihood that the PPSA will achieve its
important goal.
Conflict of Interest Disclosures: Both authors have completed and submitted the
ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Joffe reports being
a paid member of a data monitoring committee for Genzyme Corporation (now a
part of sanofi-aventis). Dr Carpenter reported no disclosures.
Funding/Support: This work was supported by grant 1UL1RR025758-01 from the
Harvard Catalyst (Drs Carpenter and Joffe) and support from the Safra Center for
Ethics, Harvard University (Dr Carpenter), Alfred Sloan Foundation (Dr Carpen-
ter), and Greenwall Foundation (Dr Joffe).
Role of the Sponsor: No sponsor or funder had any role in the preparation, re-
view, or approval of the manuscript.
REFERENCES
1. Pub L No. 111-148, 124 Stat 1025 (2010).
2. US Institute of Medicine. Conflict of Interest in Medical Research, Education,
and Practice. Washington, DC: National Academy of Sciences; 2009.
3. Chimonas S, Frosch Z, Rothman DJ. From disclosure to transparency: the use
of company payment data. Arch Intern Med. 2011;171(1):81-86.
4. Cals JW, Kotz D. Researcher identification: the right needle in the haystack.
Lancet. 2008;371(9631):2152-2153.
5. Bohne-Lang A, Lang E. Do we need a unique scientist ID for publications in
biomedicine? Biomed Digit Libr. 2005;2(1):1.
6. EnserinkM. Scientific publishing: are you ready to become a number? Science.
2009;323(5922):1662-1664.
7. Friedberg EC. Good news on the horizon: the Open Researcher and Contribu-
tor ID (ORCID). DNA Repair (Amst). 2010;9(2):102.
8. Credit where credit is due. Nature. 2009;462(7275):825.
9. US Government Web site. http://www.data.gov/. Accessed April 21, 2011.
10. US Department of Health and Human Services. Responsibility of applicants
for promoting objectivity in research forwhich public health service funding is sought
and responsible prospective contractors: request for comments. Fed Regist. 2009;
74(88):21610-21613.
COMMENTARY
2008 JAMA, May 18, 2011—Vol 305, No. 19 ©2011 American Medical Association. All rights reserved.
 at Harvard University on May 17, 2011jama.ama-assn.orgDownloaded from 
